Clinical Trials
10 trialsNCT05483933 2025-12-23
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
Shattuck Labs, Inc.
Phase 1 Completed
NCT01314105 2025-02-13
BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT02272790 2023-10-03
Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
AstraZeneca
Phase 2 Completed
NCT02580058 2023-07-10
JAVELIN Ovarian 200
Pfizer
Phase 3 Completed
NCT05868889 2023-05-24
Retrospective Multicenter Study of Elderly Patients With Ovarian Cancer Treated With Trabectedin and PLD
Grupo Español de Investigación en Cáncer de Ovario
Completed
NCT03161132 2023-01-27
ROLANDO
Grupo Español de Investigación en Cáncer de Ovario
Phase 2 Completed
NCT02431559 2022-10-10
Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT01837251 2021-07-13
Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer
AGO Research GmbH
Phase 3 Completed
NCT03562533 2019-02-28
Real-World Effectiveness of PLD in Platinum- Sensitive Recurrent Ovarian Cancer
Konkuk University Medical Center
Completed
NCT01004380 2014-07-17
Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer
Morphotek
Phase 1 Completed